BALA CYNWYD, PA / ACCESSWIRE / August 10, 2019 / Brodsky & Smith, LLC announces that class action lawsuits have been filed against the following companies for violations of federal securities laws. If you purchased any of the below-listed stocks during the referenced time periods and want to discuss your legal rights, please contact Marc Ackerman, Esquire or Jordan Schatz, Esquire at 877-534-2590. There is no cost or financial obligation to you.
FRED’S, INC. (Nasdaq:FRED)
Shares purchased between December 20, 2016 and June 28, 2017
Deadline: August 27, 2019
According to the complaint, defendants made numerous materially false and misleading statements concerning the level of regulatory risk faced by the Original Merger and the Revised Merger which would ultimately cause the termination of the Fred’s Asset Purchase Agreement. Specifically, Defendants made false and/or misleading statements: (i) downplaying or disputing contrary reports from journalists signaling regulatory turbulence in closing the merger; (ii) representing that inside knowledge of the FTC gave confidence that the deal would close.
Additional information can be found at: http://www.brodskysmith.com/cases/freds-inc-nasdaq-fred/ or call: 877-534-2590. No cost or obligation.
KARYOPHARM THERAPEUTICS, INC. (Nasdaq:KPTI)
Shares purchased between March 2, 2017 and February 22, 2019
Deadline: September 23, 2019
According to the complaint, defendants made materially false and/or misleading statements and/or failed to disclose that: Throughout the Class Period, the Company continued to tout the commercial prospects for selinexor and consistently described selinexor as having a “predictable and manageable tolerability profile” and a “very nice safety profile,” and assured investors that it was “well tolerated” by patients. Karyopharm also claimed that selinexor had the potential to be used as a new treatment for MM, with limited and manageable side effects. As a result of these misrepresentations, Karyopharm shares traded at artificially inflated prices during the Class Period.
Additional information can be found at: http://www.brodskysmith.com/cases/karyopharm-therapeutics-inc-nasdaq-kpti/ or call: 877-534-2590. No cost or obligation.
SUNLANDS TECHNOLOGY GROUP (NYSE:STG)
Shares purchased pursuant to the Company’s March 2018 initial public offering (IPO)
Deadline: August 26, 2019
According to the complaint, defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Sunlands’ student enrollment was declining; (2) Sunlands’ gross billings were declining; (3) Sunlands' marketing tactics were not as robust as described in the Registration Statement; and (4) as a result, Defendants’ statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Additional information can be found at: http://www.brodskysmith.com/cases/sunlands-technology-group-nyse-stg/ or call: 877-534-2590. No cost or obligation.
Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
SOURCE: Brodsky & Smith, LLC